Tempus AI, Inc. (NASDAQ: TEM), a technology company focused on advancing precision medicine through artificial intelligence, announced on March 11, 2025, the acquisition of Deep 6 AI, a leading AI-powered precision research platform. The acquisition, for which financial terms were not disclosed, is expected to significantly expand Tempus' clinical trial capabilities and provider network.
Deep 6 AI specializes in accelerating clinical trial recruitment and generating real-world evidence by using artificial intelligence to analyze electronic medical record (EMR) data. The company's platform mines both structured and unstructured patient data in real-time across a diverse healthcare ecosystem that includes academic medical centers, National Cancer Institute (NCI)-Designated Cancer Centers, and NCI Community Oncology Research Programs.
Strategic Expansion of Provider Network
A key asset in this acquisition is Deep 6 AI's extensive integration infrastructure, which encompasses over 750 provider site locations and more than 30 million patients. This substantial network will complement Tempus' existing connectivity efforts and broaden its reach across healthcare providers.
"Deep 6's impressive integration infrastructure is well-suited to complement our connectivity efforts, which are central to our ability to support physicians in delivering optimized care for their patients," said Eric Lefkofsky, Founder and CEO of Tempus. "This acquisition broadens our reach, adding even more providers to our platform, and enhances our ability to deploy critical applications like Next, which helps physicians close care gaps, and TIME, which helps patients find potentially life-saving clinical trials."
Enhancing AI-Powered Precision Medicine
Tempus has built one of the world's largest libraries of multimodal healthcare data, along with an operating system designed to make that data accessible and useful. The company's AI-enabled precision medicine solutions aim to deliver personalized patient care while simultaneously facilitating the discovery, development, and delivery of optimal therapeutics.
The integration of Deep 6 AI's technology is expected to strengthen Tempus' ability to match patients with appropriate clinical trials, a process that has traditionally been challenging and time-consuming for healthcare providers. By leveraging artificial intelligence to analyze patient records, the combined platform can identify eligible trial participants more efficiently and accurately.
Clinical Trial Landscape and Unmet Needs
Clinical trial recruitment remains a significant bottleneck in drug development, with many trials failing to meet enrollment targets on time. This delay can extend development timelines and increase costs for pharmaceutical companies, ultimately slowing the delivery of new treatments to patients.
Deep 6 AI's technology addresses this challenge by de-risking clinical trials and accelerating recruitment through precise patient matching. The platform's ability to analyze unstructured data—such as physician notes, pathology reports, and other text-based information—allows it to identify potential trial participants who might be missed by traditional recruitment methods that rely solely on structured data fields.
Future Integration and Market Impact
While specific integration plans were not detailed in the announcement, the acquisition is likely to strengthen Tempus' position in the growing market for AI-powered healthcare solutions. As healthcare organizations increasingly adopt artificial intelligence to improve clinical decision-making and research efficiency, platforms that can effectively analyze and utilize complex medical data are becoming increasingly valuable.
For patients, the combination of these technologies could mean faster access to clinical trials of innovative treatments, particularly in oncology and other specialty areas where Tempus has established expertise. For healthcare providers, the enhanced platform may offer improved tools for identifying optimal treatment pathways and research opportunities for their patients.
The acquisition represents another step in the ongoing consolidation of the healthcare AI sector, as companies seek to build comprehensive platforms that can address multiple aspects of clinical care and research.
